FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000446572> ?p ?o ?g. }

• W2000446572 abstract "Tyrosine kinase inhibitor (TKI) treatment for patients with chronic myeloid leukemia (CML) has dramatically improved longerterm outcomes through achievement of deep cytogenetic responses in the majority of patient cases and provided compelling clinical evidence for so-called oncogene addiction, whereby cancer cells demonstrate exquisite reliance on the continued activity of a particular protein for survival. This success story is further underscored by results from imatinib discontinuation studies, which have demonstrated that approximately 40% of patients who achieve a stable ( 2 years) 4.5-log reduction in breakpoint cluster region (BCR) –ABL transcript (MR) remain in molecular remission several years after discontinuing TKIs. In the article accompanying ours, Hehlmann et al report that with longer-term (approximately 9 years) follow-up, 70% of patients treated with imatinib achieved MR, and these responses were more common in patients who received higher doses of imatinib through a tolerability-adapted strategy. If these deep molecular responses are generally durable ( 2 years), one may expect that a substantial proportion of patients with CML will eventually be able to discontinue treatment for several years without suffering molecular relapse. Previous studies have suggested that deeper remissions are generally associated with superior outcomes; however, this is the first study to our knowledge to demonstrate that achievement of a deep molecular response (ie, MR) predicts statistically significant superior survival relative to that in patients with only a 2-log reduction in BCR-ABL transcript level (ie, MR), which has been suggested to be the minimal molecular response equivalent of a complete cytogenetic response (CCR). The fact that these results were achieved with imatinib has important economic implications in light of its patent expiration in 2015. The Philadelphia chromosome translocation that is the hallmark of CML fuses ABL (non–receptor tyrosine kinase–encoding gene) to the BCR gene, giving rise to the chimeric BCR-ABL kinase. In the process, the segment of ABL responsible for autoinhibition is lost. Additionally, BCR-mediated oligomerization of the fusion kinase leads to transphosphorylation and BCR-ABL activation, resulting in cell-cycle progression, proliferation, antiapoptotic signals, and gene transcription modulation (Fig 1). Phosphorylation of BCR-ABL at Tyr-177 allows formation of a complex between GRB2, GAB2, and SOS, which activates RAS, leading to cell proliferation through the mitogen-activated protein kinase (MAPK) pathway. RAS also activates the phosphoinositide 3-kinase (PI3K)/AKT pathway, resulting in promotion of proteosomal degradation of p27, a protein involved in maintaining G1-phase arrest; suppression of the FOXO transcription factors, which are involved in tumor suppression mechanisms and cell-cycle quiescence; and activation of mammalian target of rapamycin (mTOR), a serine/threonine kinase with multiple functions that stimulates cell survival and cell growth, enhances protein translation, and negatively regulates the cellular process of autophagy, which recycles intracellular components and facilitates survival in conditions of stress. Signal transducer and activator of transcription 5 (STAT5) activation has been demonstrated to be indispensable for leukemic cell survival. In CML cells, activation of STAT5 seems to occur independently of the canonical Janus kinase 2 (JAK2)/STAT5 pathway, and evidence for direct activation by BCR-ABL in vitro has been provided. Activated STAT5 promotes the transcription of genes that lead to cytokineindependent growth and evasion of apoptosis. Previous studies have demonstrated that CML cell lines require continued activation of at least two of the three canonical BCR-ABL– activated pathways (STAT5, PI3K/AKT, and RAS/MAPK) for survival. On binding to the ABL kinase domain, imatinib prevents ATP binding and hydrolysis, effecting apoptosis in BCR-ABL–dependent CML cells via loss of signaling through these pathways, although how BCR-ABL rewires cellular signaling to create a dependence on its activity is not clear. Mutations in the BCR-ABL kinase domain, which alter drug-binding capacity, are the most common cause of TKI resistance. This observation led to the development of the secondgeneration TKIs dasatinib, nilotinib, and bosutinib, which are notably more potent than imatinib and seem to effect deeper and faster molecular remissions than standard-dose imatinib. However, these drugs are ineffective against the BCR-ABL/T315I mutant, for which ponatinib, a pan–BCR-ABL third-generation TKI, represents the most promising treatment. Amplification of the BCR-ABL gene is a less common mechanism of imatinib resistance, which presumably leads to resistance through accumulation of increased levels of BCRABL capable of escaping the intracellular drug concentrations achieved by standard-dose imatinib. This mechanism, identified as the most frequent cause of resistance in CML cell lines, has also been observed in patients with blast-phase CML, although it seems to be uncommon in patients with chronic-phase disease. Why might higher doses of imatinib (and more-potent BCRABL TKIs) achieve faster and deeper molecular response rates, as reported by Hehlmann et al? One possible explanation is that standard-dose imatinib provides suboptimal BCR-ABL inhibition in some patients, resulting in maintenance of prosurvival signaling or allowing sufficient time for cell rewiring and avoidance of apoptosis, JOURNAL OF CLINICAL ONCOLOGY U N D E R S T A N D I N G T H E P A T H W A Y VOLUME 32 NUMBER 5 FEBRUARY 1" @default.
• W2000446572 created "2016-06-24" @default.
• W2000446572 creator A5015115182 @default.
• W2000446572 creator A5043909479 @default.
• W2000446572 date "2014-02-10" @default.
• W2000446572 modified "2023-09-23" @default.
• W2000446572 title "What Does a Deep Molecular Response Signify?" @default.
• W2000446572 cites W1490418776 @default.
• W2000446572 cites W1585894933 @default.
• W2000446572 cites W1971940453 @default.
• W2000446572 cites W1976577472 @default.
• W2000446572 cites W1983031752 @default.
• W2000446572 cites W1999614615 @default.
• W2000446572 cites W2013225336 @default.
• W2000446572 cites W2021648831 @default.
• W2000446572 cites W2024290860 @default.
• W2000446572 cites W2026359801 @default.
• W2000446572 cites W2033801757 @default.
• W2000446572 cites W2040400619 @default.
• W2000446572 cites W2057206328 @default.
• W2000446572 cites W2057827171 @default.
• W2000446572 cites W2058082901 @default.
• W2000446572 cites W2059059532 @default.
• W2000446572 cites W2061440903 @default.
• W2000446572 cites W2064367288 @default.
• W2000446572 cites W2074740152 @default.
• W2000446572 cites W2096882254 @default.
• W2000446572 cites W2104694028 @default.
• W2000446572 cites W2106266094 @default.
• W2000446572 cites W2108227401 @default.
• W2000446572 cites W2112810605 @default.
• W2000446572 cites W2116396726 @default.
• W2000446572 cites W2117356576 @default.
• W2000446572 cites W2122224021 @default.
• W2000446572 cites W2134234801 @default.
• W2000446572 cites W2138532022 @default.
• W2000446572 cites W2140102346 @default.
• W2000446572 cites W2143939343 @default.
• W2000446572 cites W2147013008 @default.
• W2000446572 cites W2150148922 @default.
• W2000446572 cites W2152648806 @default.
• W2000446572 cites W2157693529 @default.
• W2000446572 cites W2159473577 @default.
• W2000446572 cites W2163104842 @default.
• W2000446572 cites W2165537263 @default.
• W2000446572 cites W2224782492 @default.
• W2000446572 cites W2328337234 @default.
• W2000446572 cites W2329193471 @default.
• W2000446572 cites W57149238 @default.
• W2000446572 doi "https://doi.org/10.1200/jco.2013.52.8307" @default.
• W2000446572 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24297955" @default.
• W2000446572 hasPublicationYear "2014" @default.
• W2000446572 type Work @default.
• W2000446572 sameAs 2000446572 @default.
• W2000446572 citedByCount "2" @default.
• W2000446572 countsByYear W20004465722014 @default.
• W2000446572 countsByYear W20004465722015 @default.
• W2000446572 crossrefType "journal-article" @default.
• W2000446572 hasAuthorship W2000446572A5015115182 @default.
• W2000446572 hasAuthorship W2000446572A5043909479 @default.
• W2000446572 hasConcept C121608353 @default.
• W2000446572 hasConcept C126322002 @default.
• W2000446572 hasConcept C143998085 @default.
• W2000446572 hasConcept C170493617 @default.
• W2000446572 hasConcept C197934379 @default.
• W2000446572 hasConcept C2777583451 @default.
• W2000446572 hasConcept C2778375690 @default.
• W2000446572 hasConcept C2778715236 @default.
• W2000446572 hasConcept C2778729363 @default.
• W2000446572 hasConcept C2778820342 @default.
• W2000446572 hasConcept C3019892230 @default.
• W2000446572 hasConcept C42362537 @default.
• W2000446572 hasConcept C43907098 @default.
• W2000446572 hasConcept C71924100 @default.
• W2000446572 hasConceptScore W2000446572C121608353 @default.
• W2000446572 hasConceptScore W2000446572C126322002 @default.
• W2000446572 hasConceptScore W2000446572C143998085 @default.
• W2000446572 hasConceptScore W2000446572C170493617 @default.
• W2000446572 hasConceptScore W2000446572C197934379 @default.
• W2000446572 hasConceptScore W2000446572C2777583451 @default.
• W2000446572 hasConceptScore W2000446572C2778375690 @default.
• W2000446572 hasConceptScore W2000446572C2778715236 @default.
• W2000446572 hasConceptScore W2000446572C2778729363 @default.
• W2000446572 hasConceptScore W2000446572C2778820342 @default.
• W2000446572 hasConceptScore W2000446572C3019892230 @default.
• W2000446572 hasConceptScore W2000446572C42362537 @default.
• W2000446572 hasConceptScore W2000446572C43907098 @default.
• W2000446572 hasConceptScore W2000446572C71924100 @default.
• W2000446572 hasLocation W20004465721 @default.
• W2000446572 hasLocation W20004465722 @default.
• W2000446572 hasOpenAccess W2000446572 @default.
• W2000446572 hasPrimaryLocation W20004465721 @default.
• W2000446572 hasRelatedWork W1506200166 @default.
• W2000446572 hasRelatedWork W2080531066 @default.
• W2000446572 hasRelatedWork W2524976195 @default.
• W2000446572 hasRelatedWork W2529376761 @default.
• W2000446572 hasRelatedWork W2748952813 @default.
• W2000446572 hasRelatedWork W2780146991 @default.
• W2000446572 hasRelatedWork W2899084033 @default.
• W2000446572 hasRelatedWork W3032295737 @default.

• next